Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen

Cancer

Volumn 78, Issue 11, 1996, Pages 2374-2378

  Morote, Juan ^a,b   Lorente, José Antonio ^a   Encabo, Gloria ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE   (Spain)

Author keywords

bone alkaline phosphatase; bone metastases; prostate carcinoma; prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW SCINTISCANNING; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST CONTROL; ECHOGRAPHY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE NEOPLASMS; CARCINOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029828625     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961201)78:11<2374::AID-CNCR16>3.0.CO;2-Y     Document Type: Article

References (15)

1. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28:485-95.
2. Price CP. Multiple forms of human serum alkaline phosphatase: detection and quantification. Ann Clin Biochem 1993;30:355-72.
3. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1990;186:315-21.
4. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994;25:236-42.
5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-13.
6. Morote J, de Torres JA. Utility of bone scan versus tumor markers, PSA and PAP, in the monitorization of prostate cancer. Actas Urol Esp 1990;14:268-70.
7. Miller PD, Earldly Y, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostate cancer. Br J Urol 1992;70:295-8.
8. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am 1993;20:705-11.
9. Morote J, Olona M, Vila J, Reig C, Lopez MA, de Torres JA, et al. Can we eliminate bone scan in the staging of prostate cancer? Actas Urol Esp 1992;16:487-90.
10. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1992;62:195-202.
11. Garnero P, Delmas PD. Assessment of the levels of bone alkaline phosphatase with new immunometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
12. SPSS® for Windows™: Base System User's Guide. Release 6.0. Chicago: SPSS, Inc., 1993.
13. Morote J, Ruibal A, Palou J, deTorres JA, Soler A. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol 1988;14:360-6.
14. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate spe-cific antigen is superior to all other clinical parameters. J Urol 1991;145:313-8.
15. Andriole GL, Catalona WJ. Letter to the editor. J Urol 1992;147:474.